New Data Presented For SEROQUEL XRTM In Major Depressive Disorder And Generalised Anxiety Disorder

Posted by on November 18th, 2008 at 06:00am

Two studies presented today at the 8th International Forum on Mood and Anxiety Disorders (IFMAD) in Vienna demonstrated that once-daily SEROQUEL XRTM (quetiapine fumarate extended release tablets) provided significant symptom relief for elderly patients (>65 years of age) with major depressive disorder (MDD) and generalised anxiety disorder (GAD).

Spread the Love & Syndicate
  • del.icio.us
  • YahooMyWeb
  • digg
  • Furl
  • description
  • De.lirio.us
  • co.mments
  • Ma.gnolia
  • Reddit
  • Spurl
  • Psychodynamic Treatment May Help Depression. Results From A Finnish Study
  • Northstar Neuroscience Receives FDA Approval For A Clinical Study Of Its Cortical Stimulation System For The Treatment Of Major Depressive Disorder
  • Study Showed New Episodes Of Depression Delayed In People Taking Cymbalta(R)
  • New Episodes Of Depression Delayed In People Taking Cymbalta(R) - Fewer Patients On Treatment Experienced A New Episode

    • Under Depression

    Leave a Comment for New Data Presented For SEROQUEL XRTM In Major Depressive Disorder And Generalised Anxiety Disorder

    Required

    Required, hidden

    Trackback this post  |  Subscribe to the comments via RSS Feed

    Recent Blog Posts

    Categories

    Posts by Month

    Resources